Seer Q3 2026 slides: scientific gains offset by revenue guidance cut
Seer, Inc. (SEER) reported Q3 2026 revenue of $4.0M, flat YoY but up 29% QoQ. It cut FY2026 revenue guidance to $13.5M-$14.5M from $16M-$18M, citing funding constraints. Shares fell 3.73% in after-hours trading to $1.55. The company highlighted scientific progress but faces commercial growth challenges.
How this was made
The 30-second read
Why it matters
Guidance reduction and funding constraints suggest near‑term revenue weakness, but long‑term AI‑proteomics potential remains.
Market read
Earnings release with guidance cut is primary news for SEER, likely driving short‑term price decline.
What to watch
Strong cash position of $198M and recent share repurchase could support the stock despite lower guidance.
Background
Seer Inc. (NASDAQ:SEER) presented its Q3 2026 earnings, highlighting scientific progress but reduced revenue outlook.
Ticker impact
Seer reported Q3 2026 results and cut full-year revenue guidance, causing a 3.73% after‑hours share decline.
downward pressure as investors price in reduced revenue outlook
Revenue guidance lowered by ~19% due to funding constraints; shares already fell in after‑hours trading.
Market effects
Proteomics and biotech funding environment faces headwinds, may dampen sector sentiment.
US biotech investors may become more risk‑averse.
Limited to niche proteomics market; minimal broader market effect.
Counterpoint
If AI‑driven demand for deep proteomics accelerates, the guidance cut may be temporary and upside possible.
Key entities
- companySeer Inc.
US‑listed proteomics platform provider reporting earnings and guidance cut.
- executiveOmid Farokhzad
CEO of Seer who commented on long‑term prospects.

